ONCAlert | Upfront Therapy for mRCC
Videos  >  

Updates in the Treatment Landscape of AML

Eunice Wang, MD
Published Online:3:14 PM, Thu February 7, 2019


Eunice Wang, MD, chief of the leukemia service at the Roswell Park Comprehensive Cancer Center, discusses the new era of treatment for patients with acute myeloid leukemia (AML) after the approval of 3 new treatment regimens at the end of 2018.

With these approvals, physicians are questioning how necessary the standard backbone chemotherapy low-dose cytarabine and anthracycline-based treatments are; these agents have been the standard since the 1970s for younger and fitter patients.

For the last few years, physicians have been using low-dose hypomethylating agents for older patients. In the last year, there has been a breakthrough in terms of combination therapy with low-dose chemotherapy and oral agents.

All 3 of the recent approvals are oral compounds. Glasdegib (Daurismo) and venetoclax (Venclexta) in particular have expanded the treatment options for older patients who previously only had hospice and palliative options in the past.
Copyright © TargetedOnc 2019 Intellisphere, LLC. All Rights Reserved.